サルコペニア治療薬の世界市場:市場インサイト、疫学分析、市場予測

◆英語タイトル:Sarcopenia - Market Insights, Epidemiology and Market Forecast -2023-7 MM
◆商品コード:DLVE704026
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2017年4月
◆ページ数:51
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2営業日以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名使用)USD4,950 ⇒換算¥554,400見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD9,900 ⇒換算¥1,108,800見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD14,850 ⇒換算¥1,663,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

DelveInsight’s “Sarcopenia – Market Insights, Epidemiology and Market Forecast-2023-7 MM” Report provides an overview of the disease and global market size of the Sarcopenia for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the prevalent cases of Sarcopenia from 2013-2023. Sarcopenia is the progressive loss of skeletal muscle that comes with aging. Sarcopenia is multifactorial in cause. Most people begin to lose modest amounts of muscle mass after age 30, but the resulting loss of strength increases exponentially with age. Of the contributory factors relating to the development of sarcopenia inadequate protein intake, increased splanchnic extraction of amino acids, decreased muscular response to postprandial anabolic stimuli and vitamin D deficiency are directly related to nutrition.
According to DelveInsight, the market size of Sarcopenia in 7 MM is estimated to be USD XX Million by 2023 at a CAGR of 2.36% for the forecast period i.e., 2013-2023. Also the prevalence cases in 7 MM are expected to increase and reach up to 42,969,489 cases by year 2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Scope
The report will help in developing business strategies by understanding the trends shaping and driving the Sarcopenia market.
Organize sales and marketing efforts by identifying the best opportunities for Sarcopenia in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
To understand the future market competition in the 7MM market of Sarcopenia and Insightful review of the key market drivers and barriers.
To understand the regulatory scenario in major markets.

The Report also covers the detailed historical and forecasted Sarcopenia market covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.

【レポートの目次】

Report Introduction
Sarcopenia: Overview
Introduction
Pathophysiology
Symptoms
Diagnosis
Sarcopenia categories and stages
EWGSOP Conceptual Stages of Sarcopenia
Treatment
Challenges
Unmet Need
Epidemiology of Sarcopenia in 7MM
Epidemiology and Patient Population
Assumptions and Caveats
Prevalent Population of Sarcopenia in 7MM
United States
Europe
United Kingdom
France
Italy
Spain
Germany
Japan
Pipeline Drugs in Development
Enobosarm: GTX, Inc.
Product Description
Clinical Development
Advantages & Disadvantages
Product Profile
REGN-1033: Regeneron Pharmaceuticals
Product Description
Clinical Development
Advantages & Disadvantages
Product Profile
LY-2495655: Eli Lilly and Company
Product Description
Clinical Development
Advantages & Disadvantages
Product Profile
Testosterone Enanthate + Finasteride: Endo Pharmaceuticals
Product Description
Clinical Development
Advantages & Disadvantages
Product Profile
BYM338: Novartis AG
Product Description
Clinical Development
Advantages & Disadvantages
Product Profile
Sarconeos: Biophytis
Product Description
Clinical Development
Advantages & Disadvantages
Product Profile
Global Market Scenario for Sarcopenia
Sarcopenia: Country-Wise Market Analysis
7 Major Market Size of Sarcopenia (2013-2023)
Global Market Size by Geography
United States
Market size of Europe
United Kingdom
France
Italy
Spain
Germany
Japan
Market Drivers and Market Barriers for Sarcopenia
Future Prospects for Sarcopenia
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight

Table 1: Prevalent Population of Sarcopenia in 7MM (2013-2023)
Table 2: Prevalent Population of Sarcopenia in United States (2013-2023)
Table 3: Prevalent Population of Sarcopenia in United Kingdom (2013-2023)
Table 4: Prevalent Population of Sarcopenia in France (2013-2023)
Table 5: Prevalent Population of Sarcopenia in Italy (2013-2023)
Table 6: Prevalent Population of Sarcopenia in Spain (2013-2023)
Table 7: Prevalent Population of Sarcopenia in Germany (2013-2023)
Table 8: Prevalent Population of Sarcopenia in Japan (2013-2023)
Table 9: Pipeline Drugs and Mechanism of Action, 2016
Table 10: Total 7 Major Market size of Sarcopenia in USD Million (2013-2023)
Table 11: United States Market Size of Sarcopenia in USD, Million (2013-2023)
Table 12: United Kingdom Market Size of Sarcopenia in USD, Million (2013-2023)
Table 13: France Market Size of Sarcopenia in USD, Million (2013-2023)
Table 14: Italy Market Size of Sarcopenia in USD, Million (2013-2023)
Table 15: Spain Market Size of Sarcopenia in USD, Million (2013-2023)
Table 16: Germany Market Size of Sarcopenia in USD, Million (2013-2023)
Table 17:Japan Market Size of Sarcopenia in USD, Million (2013-2023)


Figure 1: Mechanisms of Sarcopenia
Figure 2: EWGSOP Screening Algorithm
Figure 3: Prevalent Population of Sarcopenia in 7MM (2013-2023)
Figure 4: Prevalent Population of Sarcopenia in United States (2013-2023)
Figure 5: Prevalent Population of Sarcopenia in United Kingdom (2013-2023)
Figure 6: Prevalent Population of Sarcopenia in France (2013-2023)
Figure 7: Prevalent Population of Sarcopenia in Italy (2013-2023)
Figure 8: Prevalent Population of Sarcopenia in Spain (2013-2023)
Figure 9:Prevalent Population of Sarcopenia in Germany (2013-2023)
Figure 10:Prevalent Population of Sarcopenia in Japan (2013-2023)
Figure 11: Total 7 Major Market Size of Sarcopenia in USD, Million (2013-2023)
Figure 12: United States Market Size of Sarcopenia in USD, Million (2013-2023)
Figure 13: United Kingdom Market Size of Sarcopenia in USD, Million (2013-2023)
Figure 14: France Market Size of Sarcopenia in USD, Million (2013-2023)
Figure 15: Italy Market Size of Sarcopenia in USD, Million (2013-2023)
Figure 16: Spain Market Size of Sarcopenia in USD, Million (2013-2023)
Figure 17: Germany Market Size of Sarcopenia in USD, Million (2013-2023)
Figure 18:Japan Market Size of Sarcopenia in USD, Million (2013-2023)


【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ サルコペニア治療薬の世界市場:市場インサイト、疫学分析、市場予測(Sarcopenia - Market Insights, Epidemiology and Market Forecast -2023-7 MM)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆